CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by American Century Companies Inc.

American Century Companies Inc. increased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,411 shares of the company’s stock after acquiring an additional 703 shares during the quarter. American Century Companies Inc.’s holdings in CRISPR Therapeutics were worth $994,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of CRSP. Capital International Investors grew its position in CRISPR Therapeutics by 27.8% in the 1st quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock worth $534,175,000 after purchasing an additional 1,702,624 shares during the last quarter. Vanguard Group Inc. grew its position in CRISPR Therapeutics by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock worth $111,564,000 after purchasing an additional 46,148 shares during the last quarter. SR One Capital Management LP bought a new position in CRISPR Therapeutics in the 1st quarter worth about $71,496,000. Avoro Capital Advisors LLC bought a new position in CRISPR Therapeutics in the 1st quarter worth about $28,599,000. Finally, Baillie Gifford & Co. grew its position in CRISPR Therapeutics by 2.4% in the 2nd quarter. Baillie Gifford & Co. now owns 405,425 shares of the company’s stock worth $21,897,000 after purchasing an additional 9,510 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Truist Financial decreased their price objective on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, August 12th. Needham & Company LLC decreased their price objective on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Rodman & Renshaw initiated coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They issued a “buy” rating and a $90.00 price objective for the company. Piper Sandler reissued an “overweight” rating and set a $105.00 target price on shares of CRISPR Therapeutics in a research note on Monday, June 17th. Finally, Guggenheim reissued a “neutral” rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $75.63.

CRISPR Therapeutics Stock Down 0.7 %

CRSP stock opened at $46.98 on Tuesday. CRISPR Therapeutics AG has a 12-month low of $37.55 and a 12-month high of $91.10. The company has a market cap of $3.99 billion, a price-to-earnings ratio of -17.27 and a beta of 1.68. The company has a 50 day moving average of $49.28 and a two-hundred day moving average of $55.76.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The business had revenue of $0.52 million for the quarter, compared to the consensus estimate of $12.31 million. During the same period last year, the firm posted ($0.98) EPS. The firm’s quarterly revenue was down 99.3% on a year-over-year basis. On average, research analysts anticipate that CRISPR Therapeutics AG will post -5.6 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.